Sepp-Lorenzino Laura — SEC Form 4 filings
SEC reporting owner CIK 1777421. 8 Form 4 filings on record with FilingPulse; latest filed 2026-06-02.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-01-10 to 2026-06-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 11,241 shares, $174,888 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 8,966 shares @ $12.18 ($109,206) in Intellia Therapeutics, Inc., filed 2025-01-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | EVP, Chief Scientific Officer | 4 | — | 3 legs · 11,241 sh · $174,888 | 4 |
| Taysha Gene Therapies, Inc. (TSHA) | Director | 3 | — | — | 6 |
| Lexeo Therapeutics, Inc. (LXEO) | Director | 1 | — | — | 1 |
Form 4 filings — Sepp-Lorenzino Laura
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-02 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | Lexeo Therapeutics, Inc. (LXEO) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 8,966 @ $12.18 | EDGAR |
| 2025-01-03 | 4 | Intellia Therapeutics, Inc. (NTLA) | Option exercise (M): 3,500 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 49,220 @ $0 · Grant/award (A): 98,440 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 37,966 @ $0 · Grant/award (A): 54,794 (derivative) @ $0 | EDGAR |
| 2024-01-10 | 4 | Intellia Therapeutics, Inc. (NTLA) | Sale (S): 1,608 @ $28.66 · Sale (S): 667 @ $29.38 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-10 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1777421 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →